Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
November 30, 2022 14:08 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
November 21, 2022 08:48 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
November 14, 2022 08:45 ET
|
Biofrontera Inc.
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
November 10, 2022 11:52 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
November 08, 2022 16:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
October 24, 2022 07:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
October 18, 2022 10:30 ET
|
Biofrontera Inc.
Four Posters Highlighting Results from Investigator-Initiated and Company-Sponsored Research with Ameluz to be Presented WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
September 29, 2022 10:04 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
September 13, 2022 08:30 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
September 06, 2022 10:31 ET
|
Biofrontera Inc.
Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass., Sept. 06, 2022 (GLOBE...